Celsion Corp
CLSN.OQ- Latest Trade
- trading lower1.9USD
- Change
- -0.09
- % Change
4.52%Negative
- Day Range
- 1.90 - 2.05
- 52-Week Range
- 1.81 - 20.25
As of Jun 26 2022. Values delayed up to 15 minutes
- Previous Close
- 1.99
- Open
- 2.05
- Volume
- 21,523.00
- 3 Month Average Trading Volume
- 6.79
- Shares Out (Mil)
- 7.10
- Market Cap
- 13.49
- Forward P/E
- -0.37
- Dividend Yield
- -99,999.99
Key Statistics
2.33333333 mean rating - 3 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 26.98
- Price To Book (Quarterly)
- 0.24
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 12.75
- Long Term Debt/Equity (Quarterly)
- 12.75
- Return On Investment (TTM)
- -41.20
- Return On Equity (TTM)
- -37.20
2021 (millions USD)
About Celsion Corp
Company Information
Celsion Corporation is a fully integrated, clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The Company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. It has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.
Address
SUITE 100, 997 LENOX DRIVELAWRENCEVILLE, NJ
08648
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Jeffrey Wayne Church
- Chief Financial Officer, Executive Vice President, Company Secretary
- Khursheed Anwer
- Executive Vice President, Chief Scientific Officer
- Nicholas Borys
- Executive Vice President and Chief Medical Officer
- Michael H. Tardugno
- Executive Chairman of the Board, President, Chief Executive Officer
- Stacy R. Lindborg
- Director
- Christine A. Pellizzari
- Director
- Donald P Braun
- Independent Director
- Augustine Chow
- Independent Director
- Frederick J. Fritz
- Independent Director
- Robert W. Hooper
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,830.50 | 0.22%Positive |
| Copper | 691.85 | -- |
| Brent Crude Oil | 113.28 | 0.14%Positive |
| CBOT Soybeans | 1,611.50 | 0.05%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,911.74 | 3.06%Positive |
| Euro STOXX 50 | 3,533.17 | -- |
| FTSE 100 | 7,208.81 | 2.68%Positive |
| Nikkei 225 | 26,768.77 | 1.04%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes